2018 Section 5 - Rhinology and Allergic Disorders

DURHAM AND PENAGOS

J ALLERGY CLIN IMMUNOL February 2016

Dropout rate

phase)

NA 0% (DB

(Continued)

Medication scores

had partial increase of local mediator release, TAME esterase ( P 5 .005), histamine

( P 5 .008), and kinin ( P 5 .0004)

number of sneezes ( P 5 .005) and reductions in

TAME esterase ( P 5 .0004), histamine

sneezes after NAC ( P 5 .57), but they

( P 5 .04), and kinin ( P 5 .07) levels.

4-5 3-4 1 1 Open phase: After 3 years of AIT, there was a

reduction in the

levels in NF after NAC.

DB, PC phase: Those who continued on

AIT maintained the treatment effects 1 year after

randomization.

Those receiving

placebo had no

significant changes in the number of

blinded after

Years

cessation Symptom scores

after

Years

cessation

therapy

Immuno-

duration (y)

duration (y)

Total

study

; 1,150 m g of

Cumulative dose

Amb a 1

Study methods and immunotherapy schedule Units

AU 480,000 AU

(open) 1 1 (DB,

Maintenance phase: Dose : 12 m g of Amb a 1 (5000 AU) Frequency : Every 2 weeks

switch to placebo. Build-up phase: Frequency : NA Dose : NA

Duration : 3

Duration : NA

PC) years

Ragweed Study description: Twenty subjects who had been

receiving SCIT

with a ragweed

extract for at least 3 years were

randomized either

to continue active treatment or to

characteristics Allergen

Patients’

Diagnosis: Ragweed- induced hay fever

Tests: ID skin test with ragweed extract.

Asthma: Patients with mild asthma were included.

10 10 Age: 18-55 years

TABLE E2. Long-term efficacy of SCIT: Randomized, double-blind, placebo-controlled clinical trials Author, year, country SCIT Placebo Naclerio et al, 25 1997, United States

169